Immunotherapy combo shows promise in ovarian cancer trial

NCT ID NCT03249142

Completed Disease control Sponsor: ARCAGY/ GINECO GROUP Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested two immunotherapy drugs, durvalumab and tremelimumab, given with chemotherapy before and after surgery for advanced ovarian cancer. The goal was to see if this combination is safe and feasible. About 69 women with stage IIIC to IV ovarian cancer took part. The results help guide future research on using immunotherapy earlier in treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: durvalumab and tremelimumab (immune checkpoint inhibitors) plus chemotherapy
What this could lead to: If successful, this could point toward a new treatment option for advanced ovarian cancer by combining immunotherapy with standard chemotherapy before surgery.
What could go wrong: This is an early feasibility study with only 69 participants, so results may not apply to all patients. Immune-related side effects are possible and could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube adenocarcinoma ovarian cancer ovarian carcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER

Contacts and locations

Locations

Centre Eugene Marquis

Rennes, France
Centre Hospitalier Lyon Sud

Pierre-Bénite, 69495, France
Groupe confluent

Nantes, 44202, France
Gustave Roussy

Villejuif, France
HEGP

Paris, France
Hôpital Cochin

Paris, France
ICM Val d'Aurelle

Montpellier, France
Institut Bergonié

Bordeaux, France
Institut René Godinot

Reims, France
Institut Ste Catherine

Avignon, France
Institut de Cancérologie de Lorraine

Vandœuvre-lès-Nancy, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.